A novel study has indicated that in case drug Enbrel failed to show effect in individuals having psoriasis then duo effectual choices, Remicade and Stelara could help provide respite. The latest research outcome indicated that the lately accepted drug Stelara could be beneficial in treating patients having moderate to acute-ranging psoriasis in case Enbrel proved ineffective. Another research outcome showed that Remicade appeared to show favourable results in psoriasis patients who had found no reprieve from use of Enbrel. Presentation of these research outcomes were done during the yearly congregation of the American Academy of Dermatology. Centocor, the manufacturer of Remicade and Stelara had provided backing for both these studies. Over seven million people from the United States ail from psoriasis, a lifetime condition typified by inflamed skin and mostly affecting joint areas. Biologic drugs created as an outcome of genetic engineering proteins – like Remicade, Enbrel  [...]